IL22RA2

Across TCGA pan-cancer cohorts, IL22RA2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated IL22RA2 data layer compared with 26 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher IL22RA2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IL22RA2 expression acts as an unfavorable survival marker.

LUAD, BLCA, and SKCM are the cancer types where IL22RA2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.158	0.835	<.001	36	view →
BLCA	DFS	Median	All	0.243	0.627	.036	6	view →
SKCM	OS	Median	II,III,IV	0.257	0.731	.027	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

IL22RA2–LUAD (OS)

Open the LUAD breakdown →